SCHEMBL601567

SCHEMBL601567

O=C(O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSC P53634 5/20 0.68
LMNA P02545 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50
ALDH1A1 P00352 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 1/20 0.48
MME P08473 3/20 0.48
CTSK P43235 1/20 0.47
KCNH2 Q12809 1/20 0.47
ACE P12821 2/20 0.47
CPA1 P15085 2/20 0.47
ACE2 Q9BYF1 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28122659 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL601566 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL21808154 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL3008134 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL11187709 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL28122660 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL31026629 1.00 CTSC (0.68) CTSCLMNATDP1HTR2CHTR2B
SCHEMBL29413816 0.96 CTSC (0.64) CTSCLMNATDP1ALDH1A1HSD17B10
SCHEMBL30015836 0.96 CTSC (0.64) CTSCLMNATDP1ALDH1A1HSD17B10
SCHEMBL30546877 0.95 CTSC (0.63) CTSCLMNATDP1HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12426782-B2 Systems and temporal alignment methods for evaluation of gestational age and time to delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-09-30 US claimed
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 US claimed
CN-120148690-A Preparation method and application of fermented soybean containing bioactive peptide 澳门科技大学 2025-06-13 CN claimed
CN-119875976-A Breeding strain for producing gellan gum and method for producing gellan gum by using strain fermentation method 江南大学 2025-04-25 CN claimed
CN-119859167-A Preparation method of ISARIDIN E cyclic ester peptide 中山大学 2025-04-22 CN claimed
CN-119224161-A Method for detecting various dipeptides in rumen fluid of ruminant 中国科学院亚热带农业生态研究所 2024-12-31 CN claimed
CN-118425362-B Organic acid metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof 中国水产科学研究院长江水产研究所 2024-12-10 CN claimed
CN-118501300-B Method for detecting total content of proline or hydroxyproline dipeptide in collagen peptide 中国海洋大学三亚海洋研究院 2024-10-11 CN claimed
US-20240315296-A1 PEPTIDE COMPOUNDS FOR FLAVOR MODULATING CJ CHEILJEDANG CORPORATION (KR) 2024-09-26 US claimed
CN-118660707-A Supermolecule self-assembly system 北京睿创康泰医药研究院有限公司 2024-09-17 CN claimed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 US claimed
EP-3853613-A1 METHODS FOR EVALUATION OF GESTATIONAL PROGRESS AND PRETERM ABORTION FOR CLINICAL INTERVENTION AND APPLICATIONS THEREOF The Board of Trustees of the Leland Stanford Junior University (US) 2021-07-28 EP claimed
WO-2020061590-A1 METHODS FOR EVALUATION OF GESTATIONAL PROGRESS AND PRETERM ABORTION FOR CLINICAL INTERVENTION AND APPLICATIONS THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-03-26 WO claimed
CN-102348693-A Methods for preparing JAK inhibitors and related intermediate compounds INCYTE CORP 2012-02-08 CN claimed
EP-2398774-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS Incyte Corporation (US) 2011-12-28 EP claimed
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION 2010-07-29 US claimed
WO-2010083283-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE CORPORATION (US) 2010-07-22 WO claimed
EP-0197794-B1 PREPARATION OF PEPTIDES WITH C-TERMINAL PROLINE AMIDE SANKYO COMPANY LIMITED (JP) 1989-12-13 EP claimed
US-4709014-A Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1987-11-24 US claimed
EP-0197794-A2 Preparation of peptides with C-terminal proline amide SANKYO COMPANY LIMITED (JP) 1986-10-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190981-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 CTSC 2746/4885LMNA 4322/4885TDP1 2955/4885
US-12377110-B2 Fospropofol methods and compositions FOS, FOSB, PFAS CTSC 2217/4885LMNA 2765/4885TDP1 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.